SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September, 2020
Commission File Number: 001-38452
MEREO BIOPHARMA GROUP PLC
(Translation of registrants name into English)
4th Floor, One Cavendish Place,
London, W1G 0QF, United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
|99.1||Notice of General Meeting dated September 4, 2020.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: September 4, 2020
|MEREO BIOPHARMA GROUP PLC|
Mereo BioPharma Group plc
Notice of General Meeting
London and Redwood City, Calif., September 4, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), Mereo or the Company, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announces a General Meeting of the Company to be held at 11:00 a.m. on 28 September 2020 at 1 Cavendish Place, London W1G 0QF, United Kingdom.
A copy of the Notice of General Meeting is available on the Companys website: https://www.mereobiopharma.com/gm-20-09 and the Notice of General Meeting or, as appropriate, a notification of its availability online, will be posted to shareholders shortly.
Under the Companies Act 2006, the directors of a public company are required to lay its annual accounts and reports before the company in general meeting by not later than the end of the period for the filing of those accounts and reports with the Registrar of Companies. The period for filing the annual accounts and reports is ordinarily six months from the accounting reference date. However, earlier this year the Company was granted a three-month extension of this period by Companies House to 30 September 2020 in respect of its annual report and accounts for the financial year ended 31 December 2019 (the Annual Accounts).
The Companys annual general meeting (the AGM) was held on 29 June 2020. The Annual Accounts were published by the Company on 16 June 2020 but not in time for them to be laid before the AGM. Accordingly, the Directors are now convening the General Meeting at which the Annual Accounts will received by the shareholders.
Attendance at the General Meeting
On 23 March 2020, the UK Government published compulsory measures on staying at home and away from others (social distancing) to address the spread of COVID-19. The measures became law in England on 26 March 2020. The Company and its shareholders are required to comply with these measures in the holding of the General Meeting. To assist companies and shareholders to comply with the measures, the UK Government has temporarily allowed companies to suspend shareholders ability to attend meetings in person. In light of these measures, it is expected that the General Meeting will be held as a closed meeting and shareholders will not be allowed to attend the General Meeting in person. Accordingly, all shareholders are encouraged to appoint the Chairman of the General Meeting as proxy to vote on the proposed resolutions. If the COVID-19 measures are continuing at the time of the General Meeting, any shareholder seeking to attend the General Meeting in person will be refused entry.
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Mereos lead oncology product candidate, etigilimab (Anti-TIGIT), has completed a Phase 1a dose escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b study in combination with nivolumab in select tumor types. Mereos rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta (OI), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency (AATD).
Mereo BioPharma Contacts:
|Mereo||+44 (0)333 023 7300|
|Denise Scots-Knight, Chief Executive Officer|
|N+1 Singer (Nominated Adviser and Broker to Mereo)||+44 (0)20 7496 3081|
|Burns McClellan (US Investor Relations Adviser to Mereo)||+1 212 213 0006|
|FTI Consulting (UK Public Relations Adviser to Mereo)||+44 (0)20 3727 1000|